Rasmussen, Bruce ORCID: 0000-0001-5779-0339 (2004) Alliance Opportunities for Aus Biotech. Working Paper. Victoria University, Melbourne, Australia.

Abstract

Forming alliances between large pharmaceutical and biotechnology companies is an established mechanism to complete the process of development and marketing for a drug initially discovered by a biotechnology company. There is evidence that for most large pharmaceutical companies this process has taken on new urgency as the implications of product pipeline deficiencies are projected to reduce the previously high rates of growth in sales and corporate earnings. Over much of the last decade biotechnology derived medicines have been providing both an increasing number and share of total new medicines approved by the FDA. Therefore it would be surprising if large pharmaceutical companies were not turning increasingly to partnerships with biotechs to generate urgently needed new products.

Search Google Scholar

Repository staff login